Posted On: 01/03/2014 12:01:33 PM
Post# of 89350
$GILD Recent News
3 top trades for 2014 6:00 a.m. Dec. 30, 2013 - Jeff Reeves
Investors warm up to Gilead's test results; shares climb 5% by close 4:49 p.m. Dec. 18, 2013 - blogs.marketwatch.com
Twitter hits record; Campbell, Starbucks head south 4:25 p.m. Dec. 10, 2013 - Saumya Vaishampayan
Speculators should retain a flexible approach 1:41 p.m. Dec. 4, 2013 - The Trading Deck
Nasdaq’s climb reflects vast shifts in global economy 10:18 a.m. Nov. 27, 2013 - Dan Strumpf
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
AbbVie shares up on Hepatitis C results, but gains may be muted 11:49 a.m. Nov. 18, 2013 - blogs.marketwatch.com
Dan Loeb ups stake in FedEx, Google, trims Yahoo 5:41 p.m. Nov. 14, 2013 - Sital S. Patel
Selling in growth-stock leaders continues 12:23 p.m. Oct. 31, 2013 - The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours 6:13 p.m. Oct. 29, 2013 - Wallace Witkowski
Gilead profit up 17% as HIV drugs top sales growth 5:06 p.m. Oct. 29, 2013 - MarketWatch.com
Gilead shares rise 1% in late trading 4:58 p.m. Oct. 29, 2013 - Laura Mandaro
Earnings season focus shifts to revenue, capex 9:52 a.m. Oct. 27, 2013 - Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector 3:32 p.m. Oct. 24, 2013 - blogs.marketwatch.com
In focus: Overbought conditions abound 8:20 p.m. Oct. 23, 2013 - Lawrence G. McMillan
Best Buy tops S&P 500; Netflix snaps losing streak 4:20 p.m. Oct. 10, 2013 - Saumya Vaishampayan
Best Buy, Gilead Sciences lead S&P 500 gainers 4:05 p.m. Oct. 10, 2013 - Polya Lesova
Gilead, Acura stand out on up day for stocks, Quest tumbles 11:27 a.m. Oct. 10, 2013 - blogs.marketwatch.com
Gilead ends leukemia study after positive results 5:09 p.m. Oct. 9, 2013 - MarketWatch.com
Citrix, Ruby Tuesday shares fall after hours 5:05 p.m. Oct. 9, 2013 - Wallace Witkowski
Pharmacyclics: As Imbruvica Commercialization Begins, Sell-Off Creates Opportunity 10:12 a.m. Today - Seeking Alpha
GILD: Get on While Biotech Remains Hot 5:15 a.m. Today - InvestorPlace.com
Gilead Seeks To Expand Its Blockbuster Hepatitis Platforms In 2014 2:27 a.m. Today - Seeking Alpha
Bullish on Gilead - Analyst Blog 12:10 p.m. Jan. 2, 2014 - Zacks.com
Maxim hikes target on Gilead as Sovaldi continues to impress 10:45 a.m. Jan. 2, 2014 - Seeking Alpha
UBS Top High Conviction Stock Picks for 2014 7:46 a.m. Jan. 2, 2014 - 247WallSt.com
The Top Five Drug Launches Of 2013 12:42 p.m. Dec. 31, 2013 - Investors Business Daily
Deutsche still bullish on Gilead after Sovaldi launch 10:36 a.m. Dec. 31, 2013 - Seeking Alpha
Gilead Sciences Inc. (GILD): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Dec. 31, 2013 - Zacks.com
Growth Portfolio Super Bowl 2:03 a.m. Dec. 31, 2013 - Seeking Alpha
All 10 Stock Sectors Post Gains in Big Year 10:18 p.m. Dec. 30, 2013 - WSJ.com
Update on RedHill Biopharma's Pipeline - Analyst Blog 6:30 p.m. Dec. 30, 2013 - Zacks.com
Should You Sell Gilead Sciences After A Successful 2013? 1:00 p.m. Dec. 30, 2013 - Seeking Alpha
Weekly CFO Sells Highlight: Facebook Inc., Google Inc., Verisk Analytics Inc., Gilead Sciences Inc. 10:27 a.m. Dec. 30, 2013 - GuruFocus.com
The Best Mutual Funds of 2013 9:13 a.m. Dec. 30, 2013 - InvestorPlace.com
Top Analyst Upgrades and Downgrades: Gilead, Teva, Textura, Twitter and More 8:05 a.m. Dec. 30, 2013 - 247WallSt.com
On the Road to Riches in Biotech 4:10 a.m. Dec. 28, 2013 - Barrons.com
Merck Plans Radical Overhaul of Drug R&D Unit 5:20 p.m. Dec. 27, 2013 - WSJ.com
Gilead Sciences Inc (GILD): Today's Featured Drugs Laggard 5:01 p.m. Dec. 27, 2013 - TheStreet.com
Genomic Health Remains Neutral - Analyst Blog 2:55 p.m. Dec. 27, 2013 - Zacks.com
Critical Alerts For Trina Solar, Gilead Sciences, Priceline, Akamai, and Anglogold Ashanti Released By InvestorsObserver 9:31 a.m. Jan. 2, 2014 - PR Newswire
Technical Briefing on Health Care Sector: Gilead Sciences, Halozyme Therapeutics, NPS Pharma, and InterMune 8:00 a.m. Dec. 26, 2013 - PR Newswire
Clinical Trial Results, Stock Movements, Grants & Donations, and Drug Resubmissions - Research Report on Gilead, WellPoint, Zoetis, Teleflex, and Orexigen 8:00 a.m. Dec. 23, 2013 - PR Newswire
Obesity Stock Plays Standing Out from the Crowd 10:04 a.m. Dec. 20, 2013 - ACCESSWIRE
Gilead Sciences Tops List of California's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking 8:00 a.m. Dec. 19, 2013 - Marketwire
Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients 8:30 a.m. Dec. 18, 2013 - BusinessWire
FDA Consents, Pending Acquisition Approvals, Program Deployments, and Stock Movements - Research Report on Gilead, Elan, Agilent, Alkermes and Hospira 8:00 a.m. Dec. 18, 2013 - PR Newswire
Critical Insider Analysis: MGM Resorts International, Groupon Inc, Gilead Sciences, Barrick Gold Corporation 9:30 a.m. Dec. 17, 2013 - ACCESSWIRE
FDA Approvals, Dividends, Promoting Diversity, Result Publications and Acquisitions - Research Report on Gilead, St. Jude Medical, Cigna, Pharmacyclics, and LifePoint 8:00 a.m. Dec. 17, 2013 - PR Newswire
Health Canada Issues Notice of Compliance for Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C 8:30 a.m. Dec. 16, 2013 - BusinessWire
U.S. FDA Approves Gilead's Once-Daily Single Tablet HIV-1 Regimen Complera(R) for Patients Switching from a Stable Regimen 4:30 p.m. Dec. 13, 2013 - BusinessWire
HealthStat Rx: Curing Hepatitis C (HCV) With Confidence 10:07 a.m. Dec. 12, 2013 - BusinessWire
Here to Track Insider Trading of Gilead Sciences, Microsoft, Halliburton 8:55 a.m. Dec. 11, 2013 - PR Newswire
Clinical Study Results, Stock Price Movements, and Acquisitions - Research Report on Gilead, Life Technologies, Jazz Pharmaceuticals, CSI, and Smith & Nephew 8:00 a.m. Dec. 11, 2013 - PR Newswire
Final Hour Buzz: Gilead Sciences, MannKind Corporation, Facebook Inc, Tiger Oil and Energy 2:46 p.m. Dec. 10, 2013 - ACCESSWIRE
Interest Stock Analysis: Gilead Sciences, Acura Pharmaceuticals, Barnes & Noble, Micron Technology 11:00 a.m. Dec. 9, 2013 - ACCESSWIRE
Stock Price Updates, FDA 510(k) Clearances, Conference Presentation and Resignations - Research Report on Gilead, Oculus Innovative Sciences, ARCA biopharma, Arena Pharma, and Tonix Pharma 8:00 a.m. Dec. 9, 2013 - PR Newswire
Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma 6:00 p.m. Dec. 8, 2013 - BusinessWire
Gilead Announces Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia 6:30 p.m. Dec. 7, 2013 - BusinessWire
U.S. Food and Drug Administration Approves Gilead's Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C 4:19 p.m. Dec. 6, 2013 - BusinessWire
3 top trades for 2014 6:00 a.m. Dec. 30, 2013 - Jeff Reeves
Investors warm up to Gilead's test results; shares climb 5% by close 4:49 p.m. Dec. 18, 2013 - blogs.marketwatch.com
Twitter hits record; Campbell, Starbucks head south 4:25 p.m. Dec. 10, 2013 - Saumya Vaishampayan
Speculators should retain a flexible approach 1:41 p.m. Dec. 4, 2013 - The Trading Deck
Nasdaq’s climb reflects vast shifts in global economy 10:18 a.m. Nov. 27, 2013 - Dan Strumpf
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
AbbVie shares up on Hepatitis C results, but gains may be muted 11:49 a.m. Nov. 18, 2013 - blogs.marketwatch.com
Dan Loeb ups stake in FedEx, Google, trims Yahoo 5:41 p.m. Nov. 14, 2013 - Sital S. Patel
Selling in growth-stock leaders continues 12:23 p.m. Oct. 31, 2013 - The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours 6:13 p.m. Oct. 29, 2013 - Wallace Witkowski
Gilead profit up 17% as HIV drugs top sales growth 5:06 p.m. Oct. 29, 2013 - MarketWatch.com
Gilead shares rise 1% in late trading 4:58 p.m. Oct. 29, 2013 - Laura Mandaro
Earnings season focus shifts to revenue, capex 9:52 a.m. Oct. 27, 2013 - Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector 3:32 p.m. Oct. 24, 2013 - blogs.marketwatch.com
In focus: Overbought conditions abound 8:20 p.m. Oct. 23, 2013 - Lawrence G. McMillan
Best Buy tops S&P 500; Netflix snaps losing streak 4:20 p.m. Oct. 10, 2013 - Saumya Vaishampayan
Best Buy, Gilead Sciences lead S&P 500 gainers 4:05 p.m. Oct. 10, 2013 - Polya Lesova
Gilead, Acura stand out on up day for stocks, Quest tumbles 11:27 a.m. Oct. 10, 2013 - blogs.marketwatch.com
Gilead ends leukemia study after positive results 5:09 p.m. Oct. 9, 2013 - MarketWatch.com
Citrix, Ruby Tuesday shares fall after hours 5:05 p.m. Oct. 9, 2013 - Wallace Witkowski
Pharmacyclics: As Imbruvica Commercialization Begins, Sell-Off Creates Opportunity 10:12 a.m. Today - Seeking Alpha
GILD: Get on While Biotech Remains Hot 5:15 a.m. Today - InvestorPlace.com
Gilead Seeks To Expand Its Blockbuster Hepatitis Platforms In 2014 2:27 a.m. Today - Seeking Alpha
Bullish on Gilead - Analyst Blog 12:10 p.m. Jan. 2, 2014 - Zacks.com
Maxim hikes target on Gilead as Sovaldi continues to impress 10:45 a.m. Jan. 2, 2014 - Seeking Alpha
UBS Top High Conviction Stock Picks for 2014 7:46 a.m. Jan. 2, 2014 - 247WallSt.com
The Top Five Drug Launches Of 2013 12:42 p.m. Dec. 31, 2013 - Investors Business Daily
Deutsche still bullish on Gilead after Sovaldi launch 10:36 a.m. Dec. 31, 2013 - Seeking Alpha
Gilead Sciences Inc. (GILD): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Dec. 31, 2013 - Zacks.com
Growth Portfolio Super Bowl 2:03 a.m. Dec. 31, 2013 - Seeking Alpha
All 10 Stock Sectors Post Gains in Big Year 10:18 p.m. Dec. 30, 2013 - WSJ.com
Update on RedHill Biopharma's Pipeline - Analyst Blog 6:30 p.m. Dec. 30, 2013 - Zacks.com
Should You Sell Gilead Sciences After A Successful 2013? 1:00 p.m. Dec. 30, 2013 - Seeking Alpha
Weekly CFO Sells Highlight: Facebook Inc., Google Inc., Verisk Analytics Inc., Gilead Sciences Inc. 10:27 a.m. Dec. 30, 2013 - GuruFocus.com
The Best Mutual Funds of 2013 9:13 a.m. Dec. 30, 2013 - InvestorPlace.com
Top Analyst Upgrades and Downgrades: Gilead, Teva, Textura, Twitter and More 8:05 a.m. Dec. 30, 2013 - 247WallSt.com
On the Road to Riches in Biotech 4:10 a.m. Dec. 28, 2013 - Barrons.com
Merck Plans Radical Overhaul of Drug R&D Unit 5:20 p.m. Dec. 27, 2013 - WSJ.com
Gilead Sciences Inc (GILD): Today's Featured Drugs Laggard 5:01 p.m. Dec. 27, 2013 - TheStreet.com
Genomic Health Remains Neutral - Analyst Blog 2:55 p.m. Dec. 27, 2013 - Zacks.com
Critical Alerts For Trina Solar, Gilead Sciences, Priceline, Akamai, and Anglogold Ashanti Released By InvestorsObserver 9:31 a.m. Jan. 2, 2014 - PR Newswire
Technical Briefing on Health Care Sector: Gilead Sciences, Halozyme Therapeutics, NPS Pharma, and InterMune 8:00 a.m. Dec. 26, 2013 - PR Newswire
Clinical Trial Results, Stock Movements, Grants & Donations, and Drug Resubmissions - Research Report on Gilead, WellPoint, Zoetis, Teleflex, and Orexigen 8:00 a.m. Dec. 23, 2013 - PR Newswire
Obesity Stock Plays Standing Out from the Crowd 10:04 a.m. Dec. 20, 2013 - ACCESSWIRE
Gilead Sciences Tops List of California's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking 8:00 a.m. Dec. 19, 2013 - Marketwire
Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients 8:30 a.m. Dec. 18, 2013 - BusinessWire
FDA Consents, Pending Acquisition Approvals, Program Deployments, and Stock Movements - Research Report on Gilead, Elan, Agilent, Alkermes and Hospira 8:00 a.m. Dec. 18, 2013 - PR Newswire
Critical Insider Analysis: MGM Resorts International, Groupon Inc, Gilead Sciences, Barrick Gold Corporation 9:30 a.m. Dec. 17, 2013 - ACCESSWIRE
FDA Approvals, Dividends, Promoting Diversity, Result Publications and Acquisitions - Research Report on Gilead, St. Jude Medical, Cigna, Pharmacyclics, and LifePoint 8:00 a.m. Dec. 17, 2013 - PR Newswire
Health Canada Issues Notice of Compliance for Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C 8:30 a.m. Dec. 16, 2013 - BusinessWire
U.S. FDA Approves Gilead's Once-Daily Single Tablet HIV-1 Regimen Complera(R) for Patients Switching from a Stable Regimen 4:30 p.m. Dec. 13, 2013 - BusinessWire
HealthStat Rx: Curing Hepatitis C (HCV) With Confidence 10:07 a.m. Dec. 12, 2013 - BusinessWire
Here to Track Insider Trading of Gilead Sciences, Microsoft, Halliburton 8:55 a.m. Dec. 11, 2013 - PR Newswire
Clinical Study Results, Stock Price Movements, and Acquisitions - Research Report on Gilead, Life Technologies, Jazz Pharmaceuticals, CSI, and Smith & Nephew 8:00 a.m. Dec. 11, 2013 - PR Newswire
Final Hour Buzz: Gilead Sciences, MannKind Corporation, Facebook Inc, Tiger Oil and Energy 2:46 p.m. Dec. 10, 2013 - ACCESSWIRE
Interest Stock Analysis: Gilead Sciences, Acura Pharmaceuticals, Barnes & Noble, Micron Technology 11:00 a.m. Dec. 9, 2013 - ACCESSWIRE
Stock Price Updates, FDA 510(k) Clearances, Conference Presentation and Resignations - Research Report on Gilead, Oculus Innovative Sciences, ARCA biopharma, Arena Pharma, and Tonix Pharma 8:00 a.m. Dec. 9, 2013 - PR Newswire
Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma 6:00 p.m. Dec. 8, 2013 - BusinessWire
Gilead Announces Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia 6:30 p.m. Dec. 7, 2013 - BusinessWire
U.S. Food and Drug Administration Approves Gilead's Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C 4:19 p.m. Dec. 6, 2013 - BusinessWire
(0)
(0)
